ANIP · Company research
ANI Pharmaceuticals, Inc. (ANIP): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
27records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Nikhil Lalwani proposes selling 5,400 shares of ANI Pharmaceuticals (ANIP). - Stock Titan | Nikhil Lalwani proposes selling 5,400 shares of ANI Pharmaceuticals (ANIP). Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo! Finance Canada | ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo Finance | ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| ANI Pharmaceuticals (ANIP) Shares Moved, What Is Behind The Attention Today? - Simply Wall Street | ANI Pharmaceuticals (ANIP) Shares Moved, What Is Behind The Attention Today? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| Under a trading plan, ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares. - Stock Titan | Under a trading plan, ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| ANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares of Company Stock - MarketBeat | ANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares of Company Stock MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| A Look at ANI Pharmaceuticals Inc (ANIP) After 3.7% Decline -- G - GuruFocus | A Look at ANI Pharmaceuticals Inc (ANIP) After 3.7% Decline -- G GuruFocus | View source ↗ | GuruFocus | Oct 13, 2026 | neutral | 0 | 0.6 |
| Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? | ANI Pharmaceuticals (ANIP) is highlighted as a stock with strong potential to beat upcoming earnings estimates. The company has demonstrated a consistent track record of earnings surprises, with an average surprise of 35.05% over the past two quarters. With a positive Earnings ESP of +6.45% and a Zacks Rank #3 (Hold), the stock shows indicators suggesting another earnings beat is likely. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? | ANI Pharmaceuticals (ANIP) is highlighted as a stock with strong potential to beat upcoming earnings estimates. The company has demonstrated a consistent track record of earnings surprises, with an average surprise of 35.05% over the past two quarters. With a positive Earnings ESP of +6.45% and a Zacks Rank #3 (Hold), the stock shows indicators suggesting another earnings beat is likely. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar | The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could beat their upcoming quarterly earnings estimates. ANI Pharmaceuticals (ANIP) has a +6.45% ESP ahead of its November 6, 2026 earnings release, while Regeneron (REGN) has a +0.23% ESP before reporting on October 30, 2026. Both stocks carry a Zacks Rank #3 (Hold) rating, and the article suggests that stocks with positive ESP combined with a Zacks Rank #3 or better have historically beaten earnings 70% of the time. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.5 | 1 |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar | The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could beat their upcoming quarterly earnings estimates. ANI Pharmaceuticals (ANIP) has a +6.45% ESP ahead of its November 6, 2026 earnings release, while Regeneron (REGN) has a +0.23% ESP before reporting on October 30, 2026. Both stocks carry a Zacks Rank #3 (Hold) rating, and the article suggests that stocks with positive ESP combined with a Zacks Rank #3 or better have historically beaten earnings 70% of the time. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.5 | 1 |
| ANIP: ANI Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits | ANIP: ANI Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| After one implant, 79.6% of treated eyes had no inflammation return for two years - Stock Titan | After one implant, 79.6% of treated eyes had no inflammation return for two years Stock Titan | View source ↗ | Stock Titan | Oct 12, 2026 | neutral | 0 | 0.6 |
| ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo Finance | ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Has Consensus Price Target of $98.00 According to Analysts - MarketBeat | ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Has Consensus Price Target of $98.00 According to Analysts MarketBeat | View source ↗ | MarketBeat | Oct 8, 2026 | neutral | 0 | 0.6 |
| How to Find Strong Medical Stocks Slated for Positive Earnings Surprises | The article explains how to identify medical stocks poised for earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) tool. It highlights that combining a positive ESP with a Zacks Rank #3 or better has historically produced 70% positive surprises and 28.3% average annual returns. Two medical stocks are featured as examples: Solventum (SOLV) with a +2.81% ESP and ANI Pharmaceuticals (ANIP) with a +6.45% ESP, both expected to report earnings in early November 2026. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| How to Find Strong Medical Stocks Slated for Positive Earnings Surprises | The article explains how to identify medical stocks poised for earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) tool. It highlights that combining a positive ESP with a Zacks Rank #3 or better has historically produced 70% positive surprises and 28.3% average annual returns. Two medical stocks are featured as examples: Solventum (SOLV) with a +2.81% ESP and ANI Pharmaceuticals (ANIP) with a +6.45% ESP, both expected to report earnings in early November 2026. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| ANI Pharmaceuticals (NasdaqGM:ANIP) Stock Forecast & Analyst Predictions - Simply Wall Street | ANI Pharmaceuticals (NasdaqGM:ANIP) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Stephen Carey Sells 2,850 Shares - MarketBeat | ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Stephen Carey Sells 2,850 Shares MarketBeat | View source ↗ | MarketBeat | Sep 30, 2026 | neutral | 0 | 0.6 |
| After selling 2,850 shares, ANI Pharmaceuticals (ANIP) CFO holds 168,993 shares. - Stock Titan | After selling 2,850 shares, ANI Pharmaceuticals (ANIP) CFO holds 168,993 shares. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| Data on an eye implant for chronic eye inflammation will be presented in a late-breaking talk Oct. 9. - Stock Titan | Data on an eye implant for chronic eye inflammation will be presented in a late-breaking talk Oct. 9. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut - Yahoo Finance | ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut Yahoo Finance | View source ↗ | Yahoo Finance | Aug 10, 2026 | neutral | 0 | 0.6 |
| ANI Pharmaceuticals (ANIP) Stock Slides As Cortrophin Concentration Clouds Profit Quality - Simply Wall Street | ANI Pharmaceuticals (ANIP) Stock Slides As Cortrophin Concentration Clouds Profit Quality Simply Wall Street | View source ↗ | Simply Wall Street | Aug 9, 2026 | neutral | 0 | 0.6 |
| ANI PHARMACEUTICALS ($ANIP) Releases Q2 2026 Earnings - Quiver Quantitative | ANI PHARMACEUTICALS ($ANIP) Releases Q2 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 7, 2026 | neutral | 0 | 0.6 |
| ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance - StockStory | ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance StockStory | View source ↗ | StockStory | Aug 7, 2026 | neutral | 0 | 0.6 |
| Is ANI Pharmaceuticals (ANIP) A Bargain Following Its Positive SYNCHRONICITY Trial Results? - Yahoo Finance | Is ANI Pharmaceuticals (ANIP) A Bargain Following Its Positive SYNCHRONICITY Trial Results? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 24, 2026 | neutral | 0 | 0.6 |
| ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q1 CY2026, Stock Soars - StockStory | ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q1 CY2026, Stock Soars StockStory | View source ↗ | StockStory | May 8, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.